Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 4Carcinoma, Medullary 4Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Thyroid Diseases 2Thyroid Cancer, Papillary 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Thyroid Carcinoma, Anaplastic 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms by Site 1Neoplasms 1Lymphoma 1Lung Diseases 1

Interventions

Specimen Handling 51Carboplatin 49pembrolizumab 45Magnetic Resonance Spectroscopy 43Pemetrexed 39Cisplatin 34Paclitaxel 24durvalumab 23osimertinib 20Nivolumab 19Gemcitabine 19Radiosurgery 17Docetaxel 17atezolizumab 14Taxes 12Radiotherapy 12Immunoglobulin G 12Disulfides 12130-nm albumin-bound paclitaxel 12Etoposide 11Educational Status 11Biopsy 11Radiation 10Drug Therapy 10Blood Specimen Collection 10Platinum 9Early Intervention, Educational 9Cetuximab 9Methods 8Bevacizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × selpercatinib × 90 days × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT04268550 2026-03-23

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Active not recruiting
124 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡